The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.

Called Donanemab, this treatment from Eli Lilly will be sold under its brand name, Kisunla, and works as an intravenous ...

The US Food and Drug Administration approved Donanemab, also called Kisunla. Tuesday's decision put the monoclonal antibody ...

Beckman Coulter will use the antibody as part of a p-tau 217 in vitro diagnostic on its DxI 9000 Immunoassay Analyzer to aid in the diagnosis of the disease.

Alzheimer’s patients can temporarily lessen their symptoms with a recent FDA-approved drug that removes amyloid, or protein, ...

British patients with early-stage Alzheimer’s disease are flying to New York to be treated with new wonder drugs following ...

The Food and Drug Administration last week approved donanemab, or Kisunla, an intravenous treatment for early stage Alzheimer ...

Following this month's FDA approval of Eli Lilly’s amyloid-busting antibody Kisunla (donanemab), the Alzheimer’s disease market is set to grow in earnest—and Lilly is already eyeing a spot at the t | ...

The FDA has recently approved Donanemab, a monoclonal antibody designed to slow the progression of early symptomatic ...

WYFF News 4's Geoff Hart will be riding with Team HartStrong for the third straight year in a feat of summertime endurance.

The Food and Drug Administration (FDA) has approved Kisunla ™ (donanemab-azbt) for the treatment of Alzheimer disease. Treatment with Kisunla should be initiated in patients with mild cognitive ...

The new diagnostic criteria automatically categorize anyone with abnormal levels of beta amyloid or tau as having Alzheimer’s disease.